Dental Implants After Cancer Treatment: The UK Pathway

Cancer treatment changes the rules for dental implants. Radiotherapy, chemotherapy and the bone-protecting drugs given alongside them all leave fingerprints on the jaw, the gums and the way bone heals. The good news is that UK clinics do place implants in cancer survivors every week, with the right pathway. The bad news is that the wrong pathway, or the wrong timing, can lead to one of the few complications nobody wants: a jaw that will not heal.

TL;DR

Dental implants after cancer treatment are possible for most UK survivors, but only after a structured assessment. Head and neck radiotherapy is the highest-risk variable, because it can cause osteoradionecrosis if implants are placed into irradiated bone without proper planning. Patients who had chemotherapy elsewhere in the body, with no head and neck radiation and no IV bisphosphonates, sit much closer to the standard pathway. UK best practice is a joint workup between the implant clinician, the oncology team and often a restorative consultant, with a CBCT scan, blood work, a drug history and a clear timing window. Expect a wait of one to two years after head and neck radiotherapy before implants are considered, and earlier for chemotherapy-only patients once recovery markers are stable.

Why cancer treatment changes implant planning

Radiotherapy and some chemotherapy regimens disrupt the cell behaviours that drive implant healing. Radiation aimed at head and neck tumours damages small blood vessels in nearby bone, leaving the area hypovascular and slower to repair. Systemic chemotherapy can temporarily knock down the immune and bone-healing response, even when the head is not in the field. Bone-modifying drugs such as IV bisphosphonates and denosumab change the way the jaw remodels for years after the last dose.

None of this rules out implants. It changes how they are planned. A clinician who treats a cancer survivor exactly like any other implant patient is taking on risk on the patient's behalf that does not need to be taken.

Head and neck radiotherapy: the central question

Radiotherapy to the head and neck is the variable that changes implant planning the most. Bone that has received a high radiation dose can develop osteoradionecrosis, where it fails to heal after any insult including a tooth extraction or implant surgery, and this risk does not disappear over time.

UK practice for these patients starts with the oncology and radiotherapy records, not the dental chair. The implant clinician needs to know the total dose to the implant site, whether the planned location was inside or outside the high-dose field, and what other treatments the patient had alongside. The Faculty of Dental Surgery at the Royal College of Surgeons of England publishes guidance on the dental management of head and neck oncology patients that most UK implant surgeons reference here.

A common rule of thumb is to wait at least twelve months after the end of radiotherapy before considering implants in irradiated bone, and many UK surgeons prefer eighteen to twenty-four. It is a soft minimum, not a green light on its own, and every plan still hinges on the dose map.

Chemotherapy without head and neck radiation

For survivors whose treatment was chemotherapy in a different part of the body, with no radiation to the jaw and no bone-modifying drugs, the implant pathway sits much closer to a standard one. The relevant questions are whether the patient is in stable remission, whether blood counts and immune function have returned to baseline, and whether any ongoing maintenance treatments interfere with surgery.

Most UK clinicians will ask for a recent letter from the oncology team confirming the patient is fit for elective surgery, and check current blood work. Timing is usually framed as waiting until the patient has been off chemotherapy for several months and is no longer immunosuppressed, with the exact wait set by the oncologist rather than the dentist. Some breast, colorectal and haematological cancer survivors fall into this group and can proceed on a near-standard timeline once cleared.

The same general health checks apply here as for any implant candidate, including diabetes status and smoking history, both of which can magnify any residual healing weakness from prior treatment.

Bisphosphonates, denosumab and MRONJ risk

A subset of cancer patients receive bone-modifying drugs to protect against bone metastases or to manage hypercalcaemia. Intravenous bisphosphonates such as zoledronic acid, and denosumab in its higher cancer-indication dose, sit in a different risk band from the oral bisphosphonates used for osteoporosis. They are associated with a higher risk of medication-related osteonecrosis of the jaw (MRONJ) after any procedure that exposes bone, including implant surgery.

Patients in this group are not categorically refused implants in the UK, but they require an explicit risk conversation, a joint plan with the prescribing oncologist, and often a more conservative approach. Our dedicated guide on bisphosphonates and implants covers the specific questions UK dentists ask, and the separate piece on osteoporosis pathways explains how oral bisphosphonate risk differs.

For cancer survivors who took bone-modifying drugs in the past but have stopped, the residual risk is debated and depends on cumulative dose and time since the last infusion. This is one of the clearest scenarios where a generalist opinion is not enough, and where a specialist oral surgeon should lead the case.

The UK multi-disciplinary pathway

The gold standard pathway for cancer survivors wanting implants in the UK is multi-disciplinary. In practice that means three voices in the planning room, even if not literally at the same time.

• The oncology team confirms current disease status, treatment history, the radiotherapy dose map if relevant, and fitness for elective surgery.
• The implant clinician, usually a specialist oral surgeon, periodontist or experienced implant dentist registered with the General Dental Council, assesses local anatomy, scans and surgical risk.
• A restorative dentist or prosthodontist plans the final teeth so the implants are positioned where the long-term restoration actually needs them, not just where bone is easiest.

For complex cases, especially after head and neck cancer, this work may happen within a hospital restorative dentistry department on NHS pathways. The NHS does fund implants in a narrow set of clinically defined situations, and post-oncology reconstruction is one of the recognised categories. Our broader explainer on who actually qualifies for NHS implants sets out where the line is drawn. For survivors outside those criteria, the pathway is private, but the multi-disciplinary structure does not change.

What an implant assessment looks like for a cancer survivor

The first appointment is more thorough than a standard implant consult. Expect a detailed treatment history, copies of oncology letters, and a discussion of current medications. The clinical examination looks at oral hygiene, gum health and remaining teeth, because uncontrolled infection elsewhere is a common reason to pause an implant plan in this group.

A CBCT scan is essentially mandatory. It maps bone height, width and density at the planned sites and can be cross-referenced against radiotherapy planning images. Our CBCT cost guide explains what these scans typically cost privately in 2026.

Blood work is often requested for patients still within a few years of chemotherapy or on continuing maintenance therapy. A clinician may want full blood count, inflammatory markers and sometimes specific tests linked to the original cancer. This is the difference between placing into a healing body and one still finding its baseline.

Timing: when to start the conversation

Many UK survivors leave the implant question until after active treatment finishes, which is sensible. The conversation, though, can usefully start earlier than the surgery itself.

For head and neck cancer patients who will lose teeth before radiotherapy, ideally the oncology and dental teams plan extractions and any future implant strategy before radiation begins. Removing problematic teeth before radiotherapy, rather than into irradiated bone afterwards, sharply reduces later complication risk.

For chemotherapy-only survivors, the practical earliest window is usually a few months after treatment ends, once blood counts have stabilised and the oncologist has signed off on elective surgery. There is rarely a clinical penalty for waiting another six or twelve months.

Success rates and what to expect

The published literature, much of it indexed on PubMed, supports the working position that implants can succeed in cancer survivors at rates approaching those of the general population, with two caveats. Patients who had high-dose radiotherapy to the implant site show somewhat lower long-term survival of the implant, and the consequences of failure are more serious because of osteoradionecrosis risk. Patients with prior IV bisphosphonate exposure show higher rates of soft tissue complications.

For survivors who fall outside the high-risk categories, success rates are broadly in line with standard UK averages, and the realistic expectations covered in our implant failure rates explainer apply. The single biggest determinant remains the quality of the planning and the experience of the operator, which matters even more here than usual.

NHS vs private: who pays for what

The funding picture for cancer survivors is more layered than for standard implant cases. Hospital-based restorative dentistry departments do treat patients whose missing teeth or jaw defects are a direct consequence of head and neck cancer surgery or radiotherapy, and implants in those cases can be NHS funded. Eligibility is decided by the consultant restorative dentist on referral, usually from oncology or oral and maxillofacial surgery, and waiting times for assessment can be several months.

For survivors of cancers in other parts of the body whose missing teeth are unrelated to the cancer itself, NHS implant funding is rarely available, and the route is private. Even in that case the multi-disciplinary planning standard does not change. The cost is private, but a survivor still benefits from a clinic that coordinates with the oncology team rather than treating the medical history as a tick-box.

The British Dental Association maintains useful background on how NHS dentistry is commissioned and where restorative implant pathways sit within it, which is helpful context if you are trying to work out whether your case might be eligible for hospital referral.

Choosing a UK clinic for a post-cancer implant

The clinician should be GDC-registered, preferably with a specialist listing in oral surgery or periodontics, with documented experience treating medically complex cases. The practice should be willing to write to the oncology team and to wait for a written reply before treatment, and should produce a written plan that names the bone work, drug history considerations and timing rationale.

Avoid any clinic that offers a same-day decision on a cancer survivor's implant case without referencing the oncology history. The headline cost matters less here than the planning rigour. Our piece on how to spot a dodgy implant quote is useful general background, but the bar for post-oncology patients sits higher still.

Private implant costs are broadly in line with our 2026 UK cost guide, with the caveat that planning fees, additional scans and bone augmentation usually add up faster in this group. Always ask for an itemised quote.

Practical preparation for the appointment

A short bit of homework saves a lot of clinic time. Bring a recent oncology summary letter, a clear list of any infused drugs, dates of any radiotherapy with the area treated, and a current medication list. If your radiotherapy was within the head and neck region, ask whether the oncology team can provide the radiation dose to the planned implant area.

Hygiene preparation matters too. Most clinicians want to see stable gum health before implants in this group, and smoking cessation is non-negotiable because the bone healing margin is already narrower.

When implants are not the right call

For some patients, the honest answer after a full assessment is that implants are not in their best interest, at least not in the higher-risk sites. High-dose irradiated bone in the posterior mandible is a classic example where some UK surgeons will steer a patient toward a well-made removable prosthesis instead, accepting the trade-off in chewing comfort to avoid the osteonecrosis risk. A clinic willing to recommend against implants in specific sites is generally one worth trusting elsewhere. Our recovery guide sets out the first month for patients who do proceed.

FAQ

Can I have dental implants if I had head and neck radiotherapy?

In many cases yes, but only after a structured assessment that includes your radiotherapy dose, the field that was treated and how long ago. UK practice usually waits at least twelve months after the end of treatment, and many surgeons prefer eighteen to twenty-four. The decision hinges on whether the implant site sat inside the high-dose field, and on whether your jaw bone shows healthy remodelling on a CBCT scan. Some sites may still be advised against, and a removable option may be recommended instead.

How long should I wait after chemotherapy before getting implants?

For patients whose treatment was chemotherapy with no head and neck radiation and no bone-modifying drugs, the wait is set by your oncologist rather than the dentist. In practice that usually means a few months after the last cycle, with blood counts back to baseline and a written fitness-for-surgery letter. Many UK clinicians prefer six to twelve months from the end of treatment as a comfortable margin, but the exact window depends on your cancer type and ongoing maintenance therapy.

Do bisphosphonates I had during cancer treatment mean I cannot have implants?

Not automatically, but they raise the risk profile. Intravenous bisphosphonates and denosumab in cancer doses are linked to medication-related osteonecrosis of the jaw, and any implant plan needs a joint conversation with the prescribing oncologist. UK surgeons will take a full drug history, and may recommend a longer healing protocol, a more conservative implant count, or in some cases an alternative restoration.

Can the NHS pay for implants for cancer survivors in the UK?

Sometimes. Patients whose missing teeth or jaw defects are a direct result of head and neck cancer surgery or radiotherapy can be referred into hospital restorative dentistry departments, where implants may be NHS funded. Survivors whose missing teeth are unrelated to the cancer rarely qualify and most proceed privately.

What is the realistic success rate for implants after cancer treatment?

Survivors outside the high-risk categories see success rates broadly in line with the UK average. Patients with prior high-dose radiation to the implant site have somewhat lower long-term survival and a higher consequence if failure occurs. Patients with prior IV bisphosphonate exposure see more soft tissue complications. The largest driver of success is the rigour of the planning and an experienced operator.

Do I need a CBCT scan before implants if I had cancer treatment?

Yes, in nearly every case. A CBCT scan maps the bone three-dimensionally and is the basis for any safe implant placement. For cancer survivors it is also the way to cross-check the implant site against radiotherapy fields. A clinic that plans implants for a cancer survivor without a CBCT is working on guesswork.